GlassScriptPhysician profile
Victor Jaramillo
NPI 1265497341
$1,158.77
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $678 · 2020: $198 · 2021: $32.89 · 2022: $204 · 2023: $14.89 · 2024: $31.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $46.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $46.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $250.76 | 2019-2020 | |
| Abbvie INC. | $239.12 | 2021-2023 | |
| Sunovion Pharmaceuticals INC. | $198.09 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $142.79 | 2019-2020 | |
| Amgen INC. | $142.40 | 2019-2020 | |
| Lilly USA, LLC | $60.91 | 2019-2020 | |
| Inspire Medical Systems, INC. | $31.39 | 2024 | Inspire |
| Genzyme Corporation | $20.09 | 2019 | |
| Biogen, INC. | $19.93 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.21 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.86 | 2020 | |
| Sk Life Science, INC. | $13.06 | 2020 | |
| Impel Pharmaceuticals INC. | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Jaramillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.